Search clinical trials for: Ramucirumab Paclitaxel

Total 4134 results

University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
BioSante Pharmaceuticals; David H. Koch Charitable Foundation

Completed

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Prostate Cancer Adenocarcinoma in Situ

United States
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
Fox Chase Cancer Center
Bristol-Myers Squibb; Eli Lilly and Company

Recruiting

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Non Small Cell Lung Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
Novartis Pharmaceuticals

Completed

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

Metastatic or Locally Advanced Solid Tumors

Netherlands, Spain, Germany, Switzerland, Belgium
Arkadiusz Z. Dudek, MD
Bristol-Myers Squibb; Eli Lilly and Company; HealthPartners Institute Regions...

Active, not recruiting

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Mesothelioma, Malignant

United States
Eli Lilly and Company

Withdrawn

A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Melanoma | Liver Metastasis

United States
Eli Lilly and Company

Completed

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Italy, United States, Spain, France, Germany, Australia, New Zealand
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
Nanfang Hospital of Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Essential Tremor

China
Cook Group Incorporated

Completed

Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses (XPEDITE)

Peripheral Arterial Disease (PAD)

Germany, New Zealand
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Pancreatic Cancer

China
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

Urothelial Carcinoma

Spain, United States, Poland, Romania, Taiwan, Ukraine, Netherlands, Mexico, Japan, France, Germany, Belgium, Greece, Russian Federation, Turkey, Canada, Israel, Italy, United Kingdom, Denmark, Korea, Republic of, Australia, Hungary
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Gastric Cancer | Gastroesophageal Junction Region (GEJ) Cancer

Japan
Eli Lilly and Company

Completed

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Malignant Solid Tumor

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer

Breast Cancer | Metastatic Breast Cancer

Japan
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Ovarian Cancer
Qilu Hospital of Shandong University

Recruiting

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
M.D. Anderson Cancer Center

Active, not recruiting

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
City of Hope Medical Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Ovarian Cancer | Peritoneal Cavity Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
University of Texas Southwestern Medical Center
Celgene

Completed

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER

United States
Fudan University

Unknown

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Chengdu Kanghong Biotech Co., Ltd.

Unknown

Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy

Gastric Cancer | Gastroesophageal Cancer
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
First Affiliated Hospital of Zhejiang University
Hangzhou Dihua Biotechnology Co., LTD.

Recruiting

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Jilin University

Not yet recruiting

Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Breast Cancer Stage

China
Tata Memorial Hospital

Active, not recruiting

A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

India
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma

United States
Changhai Hospital

Completed

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

Cirrhosis, Liver | Upper Gastrointestinal Bleeding

China
Akeso

Recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer

China
Hutchison Medipharma Limited

Completed

A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
University of Ulm
B. Braun Melsungen AG

Completed

The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO)

Coronary Artery Disease | Chronic Total Occlusion | Native Coronary Artery

Germany
Vascular Biogenics Ltd. operating as VBL Therapeutics
GOG Foundation

Completed

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL)

Recurrent Platinum Resistant Ovarian Cancer

United States, Israel, Japan, Poland, Spain
Shanghai Yizhong Biotechnology Co., Ltd.

Unknown

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Non-Small Cell Lung Cancer(NSCLC)

China
Junling Li

Unknown

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Extensive-Stage Small Cell Lung Cancer

China
Tao OUYANG

Completed

Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer

Breast Cancer

China
Zhejiang University

Unknown

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer

Non Small Cell Lung Cancer

China
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Onxeo
Spectrum Pharmaceuticals, Inc

Completed

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Carcinoma of Unknown Primary

United States, Germany, France, Denmark
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Inflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative

United States
Gruppo Oncologico Italiano di Ricerca Clinica

Completed

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NabucCO)

Metastatic Pancreatic Cancer

Italy

Search clinical trials for: Ramucirumab Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations